{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:22:26Z","timestamp":1783682546600,"version":"3.55.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activities of several tricyclic heteroaryl isothiazolones (HITZs) against an assortment of gram-positive and gram-negative clinical isolates were assessed. These compounds target bacterial DNA replication and were found to possess broad-spectrum activities especially against gram-positive strains, including antibiotic-resistant staphylococci and streptococci. These included methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA), vancomycin-nonsusceptible staphylococci, and quinolone-resistant strains. The HITZs were more active than the comparator antimicrobials in most cases. For gram-negative bacteria, the tested compounds were less active against members of the family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            but showed exceptional potencies against\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            ,\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            , and\n            <jats:italic>Neisseria<\/jats:italic>\n            spp. Good activity against several anaerobes, as well as\n            <jats:italic>Legionella pneumophila<\/jats:italic>\n            and\n            <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n            , was also observed. Excellent bactericidal activity against staphylococci was observed in time-kill assays, with an approximately 3-log drop in the numbers of CFU\/ml occurring after 4 h of exposure to compound. Postantibiotic effects (PAEs) of 2.0 and 1.7 h for methicillin-susceptible\n            <jats:italic>S. aureus<\/jats:italic>\n            and MRSA strains, respectively, were observed, and these were similar to those seen with moxifloxacin at 10\u00d7 MIC. In vivo efficacy was demonstrated in murine infections by using sepsis and thigh infection models. The 50% protective doses were \u22641 mg\/kg of body weight against\n            <jats:italic>S. aureus<\/jats:italic>\n            in the sepsis model, while decreases in the numbers of CFU per thigh equal to or greater than those detected in animals treated with a standard dose of vancomycin were seen in the animals with thigh infections. Pharmacokinetic analyses of treated mice indicated exposures similar to those to ciprofloxacin at equivalent dose levels. These promising initial data suggest further study on the use of the HITZs as antibacterial agents.\n          <\/jats:p>","DOI":"10.1128\/aac.01315-06","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T01:48:47Z","timestamp":1169516927000},"page":"1259-1267","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["In Vitro and In Vivo Antibacterial Activities of Heteroaryl Isothiazolones against Resistant Gram-Positive Pathogens"],"prefix":"10.1128","volume":"51","author":[{"given":"Michael J.","family":"Pucci","sequence":"first","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Podos","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy L.","family":"Thoma","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Thanassi","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas D.","family":"Buechter","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gohar","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Gerald A.","family":"Vigliotti","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton J.","family":"Bradbury","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Achillion Pharmaceuticals, New Haven, Connecticut 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"16","volume":"12","year":"2006","unstructured":"Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect.12(Suppl. 1):16-23.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_3_2","first-page":"325","volume":"49","year":"2005","unstructured":"Bogdanovich, T., D. Esel, L. M. Kelley, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. M. Ednie, D. B. Hoellman, and P. Appelbaum. 2005. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob. Agents Chemother.49:325-3333.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550140037020"},{"key":"e_1_3_2_5_2","first-page":"2116","volume":"288","year":"2002","unstructured":"Centers for Disease Control and Prevention. 2002. Vancomycin resistant Staphylococcus aureus\u2014Pennsylvania, 2002. JAMA288:2116.","journal-title":"JAMA"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058023"},{"key":"e_1_3_2_7_2","first-page":"379","volume":"14","year":"1988","unstructured":"Chu, D. T., P. B. Fernandes, A. K. Claiborne, L. Shen, and A. G. Pernet. 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis, and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res.14:379-383.","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_3_2_8_2","first-page":"215","volume":"16","year":"1990","unstructured":"Chu, D. T., I. M. Lico, A. K. Claiborne, J. J. Plattner, and A. G. Pernet. 1990. Structure-activity relationship of quinolone antibacterial agents: the effects of C-2 substitution. Drugs Exp. Clin. Res.16:215-224.","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/491711"},{"key":"e_1_3_2_10_2","first-page":"296","year":"1996","unstructured":"Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins Co., Baltimore, MD.","journal-title":"Antibiotics in laboratory medicine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.12.2617"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(03)00140-8"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.191-195.2002"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1119-1121.2002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/499404"},{"key":"e_1_3_2_17_2","unstructured":"National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 6th ed. M7-A6. National Committee for Clinical Laboratory Standards Wayne PA."},{"key":"e_1_3_2_18_2","unstructured":"National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard 6th ed. M11-A6. National Committee for Clinical Laboratory Standards Wayne PA."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1345"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(98)80083-0"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3963-3965.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_23_2","first-page":"2200","volume":"61","year":"2004","unstructured":"Poole, K. 2004. Resistance to beta-lactam antibiotics. Cell. Mol. Life Sci.61:2200-2223.","journal-title":"Cell. Mol. Life Sci."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3697-3701.2004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.187.7.2395-2405.2005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1181"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm060844e"},{"key":"e_1_3_2_28_2","first-page":"1272","volume":"16","year":"2005","unstructured":"Wiles, J. A., Q. Wang, E. Lucien, A. Hashimoto, Y. Song, J. Cheng, C. Marlor, Y. Ou, S. D. Podos, J. A. Thanassi, C. L. Thoma, M. Deshpande, M. J. Pucci, and B. J. Bradbury. 2005. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. Bioorg. Med. Chem. Lett.16:1272-1276.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.11.064"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01315-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01315-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:20:20Z","timestamp":1645471220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01315-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1128\/AAC.01315-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.01315-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"2006-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-01-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}